A Study of Olanzapine in Participants With Bipolar Disorder.
Recruiting · NCT07263191 · Observational (researchers observe without assigning treatment) · Lead sponsor: Boryung Pharmaceutical Co., Ltd
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side effect of olanzapine, in preventing weight gain.
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients who have signed the informed consent after receiving information about the purpose and method of this study.
- Patients diagnosed with bipolar disorder and scheduled to receive olanzapine.
- Patients who understand the contents of the survey and can answer the questions directly.
Exclusion criteria
- Female patients who are pregnant, have childbearing potential, or are breastfeeding.
- Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
- Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.
Where it is running
1 location listed.
- CHA Bundang Medical Center - Seongnam, South Korea